Aug. 2005 – Litigation and its Discontents
Investors who follow our High-Yield Dow model have been steadily accumulating Merck since last October, shortly after news broke that the firm could face enormous lawsuits related to its blockbuster drug Vioxx. Most recently a Texas jury delivered a $253 million verdict against the firm. Texas law limiting punitive damages will reduce the award substantially […]
Aug. 2005 – Litigation and its Discontents Read More »
